2 Greenway Plaza
173 articles about Bellicum Pharmaceuticals
Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD AndersonBellicum’s proprietary technology licensed for use in CD19 CAR NK program
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The University of Texas MD Anderson Cancer Center exercised its option to license Bellicum’s CaspaCIDe® safety switch technology.
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented a poster showing preclinical data from its natural killer (NK) cell chimeric antigen receptor (CAR) program at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Md.
Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the third quarter 2019 and provided an operational update.
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract for a preclinical investigation from its natural killer cell chimeric antigen receptor (CAR) program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the third quarter of 2019 after the close of U.S. markets on Wednesday, November 6, 2019.
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
(BLCM) Alert: Johnson Fistel, LLP Announces Investigation of Bellicum Pharmaceuticals, Inc.; Long Term Investors Encouraged to Contact Firm
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) ("Bellicum") and certain of its officers.
BioSpace Movers and Shakers for Oct. 15
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock.
Bellicum Pharmaceuticals Appoints Dr. William Grossman as CMO
Dr. Grossman joins Bellicum from Genentech/Roche.
The company is now waiting for the FDA to determine a path forward in resuming clinical studies.
Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children With Blood Cancers and Nonmalignant Diseases
112 pediatric patients with a median follow-up of 18 months were reviewed in an oral presentation at the 59th Annual Meeting of the American Society of Hematology.
Bellicum Reports Third Quarter 2017 Financial Results
Bellicum reported a net loss of $23.4 million for the third quarter of 2017 and $69.9 million for the nine months ended September 30, 2017.
TapImmune Brings on Former Bellicum Exec as New CEO
Bellicum Reports Second Quarter 2017 Financial Results And Provides Corporate Update
Bellicum Appoints Gregory Naeve As Chief Business Officer
Bellicum To Report Second Quarter 2017 Financial Results And Host Conference Call And Webcast On August 8, 2017
Bellicum Reports Clinical Results Of BPX-501 In Pediatric Leukemias At The 22nd Congress Of The European Hematology Association